JB Therapeutics

About:

JB Therapeutics is a clinical-stage biopharmaceutical company developing innovative therapies for orphan inflammatory diseases.

Website: http://www.jbtherapeutics.com

Twitter/X: jbtherapeutics

Top Investors: Maine Angels, Boston Harbor Angels

Description:

JB Therapeutics is a clinical stage biopharmaceutical company developing the first new class of analgesic agents in two decades. Their lead compound, JBT-101, is a potent CB1 and CB2 agonist with demonstrated efficacy in several animal models of pain and inflammation. It has also completed a Phase II clinical study in chronic refractory neuropathic pain. JBT-101 is currently being developed as a potential disease modifying treatment for osteoarthritis. JBT-101 also represents a platform for combination with other anti-inflammatory and analgesic agents as well as various drug delivery strategies including ointment and gels, topical patches, and timed release formulations.

Total Funding Amount:

$687000

Estimated Revenue Range:

Less than $1M

Headquarters Location:

Newton Center, Massachusetts, United States

Founded Date:

2009-01-01

Contact Email:

info(AT)jbtherapeutics.com

Founders:

Mark Tepper

Number of Employees:

1-10

Last Funding Date:

2014-01-01

IPO Status:

Private

Industries:

© 2025 bioDAO.ai